Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
39 studies found for:    AUSTRALIA ANTIGEN
Show Display Options
Rank Status Study
1 Recruiting Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test Before Immunosuppressive Therapies?
Condition: Hepatitis B
Intervention: Other: HBV core antibodies testing. • Real time PCR testing.
2 Recruiting Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration
Condition: HBV Carrier
Interventions: Dietary Supplement: Standard Dose Spirulina Platensis;   Other: Zero Spirulina Platensis;   Dietary Supplement: Double Dose Spirulina Platensis
3 Completed A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Cyclophosphamide Doxorubicin Vincristine Lamivudine
4 Completed Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System
Condition: Hepatitis B
Interventions: Biological: Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.;   Biological: EngerixTM-B;   Biological: Placebo
5 Completed Optimization of Antiviral Therapy of Chronic HBV Infection
Conditions: Australia Antigen Positive;   Hepatitis B;   Adverse Effects
Intervention: Drug: Interferon Alfa-2a add on ADV
6 Active, not recruiting Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load
Condition: Chronic Hepatitis B
Intervention: Drug: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
7 Completed Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B
Condition: Chronic Hepatitis B
8 Completed Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients
Condition: Hepatitis B
9 Completed
Has Results
Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)
Condition: Hepatitis B
Intervention: Procedure: Blood sampling
10 Completed Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers
Conditions: Active Immunity;   Healthy;   Stem Cell Transplantation
11 Recruiting Off Treatment Durability in Chronic Hepatitis B With Good Immune Control
Condition: Chronic Hepatitis B
Intervention: Other: Treatment cessation
12 Completed
Has Results
Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine
Condition: Hepatitis B
Interventions: Biological: Engerix-B™;   Biological: Fendrix™;   Biological: GSK Biologicals' Hepatitis B vaccines (GSK223192A);   Biological: HBsAg (Booster injection)
13 Not yet recruiting Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
Conditions: Dysplastic Nodule of Liver;   Chronic Hepatitis B
Intervention: Procedure: minimally invasive ablation therapies
14 Completed A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers
Conditions: Hepatitis B;   Neoplasms
Intervention: Drug: Lamivudine
15 Completed Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers
Condition: Chronic Hepatitis B
Interventions: Drug: Vaccine+HBIG;   Drug: Vaccine+Placebo
16 Completed Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine
Condition: Hepatitis B
Interventions: Biological: DTPa-HBV-IPV/Hib vaccine;   Biological: DTPa-IPV/Hib vaccine;   Biological: EngerixTM-B
17 Terminated Study of ARC-520 in Patients With Chronic Hepatitis B Virus
Condition: Hepatitis B, Chronic
Interventions: Drug: ARC-520;   Drug: Placebo
18 Terminated A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic HBV Infection
Condition: Hepatitis B
Interventions: Drug: ARC-520;   Other: Placebo
19 Terminated A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic HBV Infection
Condition: Hepatitis B
Interventions: Drug: ARC-520 Injection;   Other: Placebo
20 Terminated Study of ARC-520 in Patients With HBeAg (Hepatitis B e Antigen) Positive Chronic Hepatitis B Virus
Condition: Chronic Hepatitis B
Interventions: Drug: ARC-520;   Drug: Placebo;   Drug: Entecavir;   Drug: Tenofovir

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.